Press Releases

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on June 15, 2010 to shareholders of record on May...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2010 on Thursday, April 29, 2010 at approximately 8:00 a.m. (ET). The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has been named as an authorized generic partner by Ferndale Laboratories and has launched an authorized generic of Analpram HC®...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) and Graceway Pharmaceuticals, LLC., (based in Bristol, TN) today announced that they have entered into an agreement to settle all existing patent...

Perrigo Company of South Carolina, Inc. (NASDAQ: PRGO)(TASE: PRGO) announced today that it won two favorable jury verdicts against Rexall Sundown, Inc. in an unfair competition lawsuit that was...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that, together with its partner Cobrek Pharmaceuticals, Inc., it has agreed to settle all Hatch-Waxman litigation relating to...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that together with its partner Cobrek Pharmaceuticals, Inc. final approval has been received from the U.S. Food and Drug Administration...

-- PBM Holdings is the world's largest manufacturer and marketer of infant formulas for the store brand market -- All cash transaction with a purchase price of $808 million -- Acquisition expected...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor™. Zaditor™ is a sterile...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive purchase agreement to acquire Orion Laboratories Pty, Ltd. for approximately $48 million in cash. Based...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Shampoo, 1%, a...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that a federal court has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600...

-- Fiscal second quarter revenue from continuing operations increased $46 million, or 9%, to $583 million -- Fiscal second quarter adjusted income from continuing operations increased 56% to $65...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on March 16, 2010 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2010 on Tuesday, February 2, 2010 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced it will implement a labeling program to help consumers more clearly identify more than 200 of the company's over-the-counter store-brand...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Sidoti Emerging Growth Conference on Friday, November 20, at 3:15 p.m....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...

-- Fiscal first quarter revenue from continuing operations increased $72 million, or 16%, to $528 million -- Fiscal first quarter GAAP income from continuing operations increased 59% to $61...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 a.m. (ET). The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Duac® Gel (clindamycin phosphate (1%) and benzoyl peroxide (5%) gel) filed by the Stiefel...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will hold its Investor Day from 8:30 a.m. to approximately 12:00 p.m. EDT on September 29, at the NASDAQ MarketSite located at 4 Times Square in New...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has purchased the ANDA for clindamycin phosphate (1%) and benzoyl peroxide (5%) gel from KV Pharmaceutical for $14 million in...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 27, 2009. Perrigo's Chairman and CEO Joseph C. Papa commented, "Our sales topped...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on September 15, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2009 on Tuesday, August 18, 2009 at approximately 8:00 a.m. (ET). The Company...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (previously Barr Laboratories Inc.) has received final approval from...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Synthon Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution...

-- Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million as compared to $481 million this quarter a year ago -- Fiscal third quarter earnings from...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on June 16, 2009 to shareholders of record on May...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10%...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that has begun shipping over-the-counter (OTC) Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg. The product will be marketed...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 second quarter and six months that ended December 27, 2008. Perrigo Company (in thousands, except per...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on March 17, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal year 2009 on Tuesday, February 3, 2009 at approximately 8:00 a.m....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg) has been settled with Perrigo taking a license under all...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today acknowledges the settlement of patent litigation brought by Sanofi-Aventis (NYSE: SNY) against Barr Laboratories, Inc. a subsidiary of Barr...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired Unico Holdings for approximately $49 million in cash. Based in Lake Worth, Florida, privately-held Unico is the...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 first quarter that ended September 27, 2008. Perrigo Company (in thousands, except per share amounts)...